| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chairman and CEO | Director | Chairman, CEO and President
2 companies
Henry A Fernandez is Chairman and CEO at MSCI and has filed Form 4s across 2 companies. Henry A Fernandez's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.1B at current prices.
Historically, Henry A Fernandez's trades have earned a middling insider score of 61/100 across 10 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -0.2%.
The biggest single holding is MSCI (~$1.1B) as Chairman and CEO. Net of sales, the MSCI filings show accumulation of 27,027 shares.
Henry A Fernandez has 60 Form 4 filings on record from January 2015 to May 2026, across 2 companies: Chairman and CEO at Msci (MSCI), 2015–2026; Director at Royalty Pharma (RPRX), 2020–2025.
The 136 reported transactions were 52 open-market purchases, 37 stock awards, 21 tax withholdings and 16 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 9 purchases worth about $32.5M and 1 sale worth about $7.7M.
The largest open-market purchase was 12,400 shares of MSCI at an average $542.87 on July 25, 2025, about $6.7M. Twelve months later MSCI was up 1%.
The only open-market sale was 29,873 shares of MSCI at an average $256.63 on November 22, 2019, about $7.7M.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | MSCI Msci Inc. | Chairman and CEO | Buy | 4,000 | $562.40 | $2,249,591.42 | +0.2% | +2.4% | - | |
| Feb 17, 2026 | MSCI Msci Inc. | Chairman and CEO | Buy | 6,800 | $523.56 | $3,560,238.80 | +0.5% | +12.0% | - | |
| Dec 5, 2025 | MSCI Msci Inc. | Chairman and CEO | Buy | 12,500 | $536.14 | $6,701,731.56 | +3.9% | +5.2% | - | |
| Jul 25, 2025 | MSCI Msci Inc. | Chairman and CEO | Buy | 12,400 | $542.87 | $6,731,598.85 | +3.9% | -1.4% | +0.8% | |
| Feb 24, 2025 | MSCI Msci Inc. | Chairman and CEO | Buy | 5,300 | $574.51 | $3,044,902.00 | +0.4% | -1.2% | -4.3% | |
| Dec 5, 2024 | MSCI Msci Inc. | Chairman and CEO | Buy | 2,900 | $612.80 | $1,777,119.10 | +0.9% | -6.1% | -11.7% | |
| Apr 25, 2024 | MSCI Msci Inc. | Chairman and CEO | Buy | 13,000 | $465.92 | $6,056,955.46 | +4.1% | +15.0% | +15.3% | |
| Feb 24, 2022 | RPRX Royalty Pharma Plc | Director | Buy | 32,500 | $37.49 | $1,218,373.00 | +126.5% | +6.7% | -2.7% | |
| Feb 25, 2021 | RPRX Royalty Pharma Plc | Director | Buy | 25,700 | $46.83 | $1,203,479.60 | New | - | - | |
| Nov 22, 2019 | MSCI Msci Inc. | Chairman and CEO | Sale+OE | 29,873 | $256.63 | $7,666,447.98 | -1.7% | - | - |